RPRX

Royalty Pharma
D

RPRX

Arincen67/100B
67.290
USD
-0.26
(-0.38%)
Post Trading·68.800USD+1.510(+2.24%)
Last updated: · Delayed 15 min
Fair value63.11Plus+7%48Price 67.2994
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
OverviewFinancialsForecastEarningsDividendsCompany

Royalty Pharma net income 2015–2026

Royalty Pharma earned 145.00M USD in Q3 FY2026, the three months to 30 September 2026, down 49.7% on the same quarter a year before. Royalty Pharma's net income over the last twelve months was 672.09M USD, down 12.1% on the twelve months before. In fiscal year 2025 it earned 770.95M USD, down 10.2% on the year before.

Last updated 6 Nov 2026 · Next report 10 Feb 2027

Net income

Net income · +2.9% a year over 10 yearsNet margin

Growth

Fiscal yearPeriod endingNet incomeGrowthNet marginRevenue
TTM30 Sept 2026672.09M-12.14%25.68%2.62B
FY202531 Dec 2025770.95M-10.25%32.42%2.38B
FY202431 Dec 2024858.98M-24.31%37.95%2.26B
FY202331 Dec 20231.13B+2,549.50%48.20%2.35B
FY202231 Dec 202242.83M-93.09%1.91%2.24B
FY202131 Dec 2021619.73M-36.44%27.07%2.29B
FY202031 Dec 2020975.04M-58.48%45.94%2.12B
FY201931 Dec 20192.35B+70.46%129.45%1.81B
FY201831 Dec 20181.38B+13.86%76.76%1.79B
FY201731 Dec 20171.21B+113.82%75.72%1.60B
FY201631 Dec 2016565.91M-2.67%30.14%1.88B
FY201531 Dec 2015581.43M—35.19%1.65B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Royalty Pharma's profit

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.